BridgeBio Pharma (NASDAQ:BBIO) is a biopharmaceutical company dedicated to discovering, developing, and delivering breakthrough medicines for genetic diseases. The company focuses on translating scientific discoveries into drugs for patients with genetic diseases and cancers with clear genetic drivers. BridgeBio operates on a unique model that bridges the gap between promising scientific research and the delivery of effective therapies to the people who need them the most. The company is involved in various projects across a broad range of therapeutic areas, aiming to bring transformative medicines to individuals suffering from genetic diseases and cancers as quickly and safely as possible. Their objective is to use their agile and collaborative approach to accelerate the pace of genetic medicine development, making a profound difference in the lives of patients and their families.